Selective COX-2 inhibition is associated with decreased mucosal damage induced by acid and pepsin in rabbit esophagitis

Inflammation

Volumn 27, Issue 1, 2003, Pages 21-29

  Lanas, Angel ^a   Jiménez, Pilar ^a   Ferrández, Angel ^a   Escartín, Alfredo ^a   Arenas, Juan ^a   Esteva, Francisco ^a   Ortego, Javier ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

COX 2 inhibition; Esophagitis; Prostaglandins

Indexed keywords

3 (3 FLUOROPHENYL) 4 (4 METHANESULFONYL) 5,5 DIMETHYL 5H FURAN 2 ONE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; PEPSIN A; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGITIS; ESOPHAGUS; HISTOPATHOLOGY; NONHUMAN; RABBIT; STOMACH MUCOSA; TREATMENT OUTCOME;

ACIDS; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ESOPHAGITIS; FURANS; INDOMETHACIN; ISOENZYMES; MOUTH MUCOSA; PEPSIN A; PIROXICAM; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RABBITS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0037300413     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022635127814     Document Type: Article

References (33)

1. Santucci, L. L. Patoia, F. Fiorucci, D. Favoro, and A. Morelli. 1990 Oesophageal lesions during treatment with piroxicam (Letter). B. M. J. 300:1018.
2. Lanas, A. and B. I. Hirschowitz. 1991. Significant role of aspirin use in patients with esophagitis. J. Clin. Gastroenterol. 13:622-627.
3. El-Serag, H. B. and A. Sonnenberg. 1997. Association of esophagitis and esophageal strictures with diseases treated with non-steroideal antiinflammatory drugs. Am. J. Gastroenterol. 92:52-56.
4. Stein, B. E., M. L. Schwartzman, M. A. Carroll, R. E. Stahl, and W. S. Rosenthal. 1989. Role of arachidonic acid metabolites in acid-pepsin injury to rabbit esophagus. Gastroenterology. 97:278-283.
5. Eastwood, G. L., B. D. Beck, D. O. Castell, F. C. Brown, and J. R. Fletcher. 1981. Beneficial effect of indomethacin on acid-induced esophagitis in cats. Dig. Dis. Sci. 26:601-608.
6. Tochner, Z., M. Barnes, J. B. Mitchell, K. Orr, E. Glatstein, and A. Russo. 1990. Protection by indomethacin against acute radiation esophatitis. Digestion. 47:81-87.
7. Northway, M. G., G. L. Eastwood, H. I. Libshitz, M. S. Feldman, J. J. Mamel, and I. A. Szwarc. 1982. Antiinflammatory agents protect opossum esophagus during radiotherapy. Dig. Dis. Sci. 27:923-928.
8. Kahrilas, P. J. and W. J. Hogan. 1993. Gastroesophageal reflux disease. In: Gastrointestinal Diseases, Sleisenger, M. H. and J. S. Fordtan, eds. Philadelphia: Saunders, Volume 1, pp. 378-401.
9. Ismail-Beigi, F., P. F. Horton, and C. E. Pope. 1970. Histological consequences of gastroesophageal reflux in men. Gastroenterology, 58:163-174.
10. Ismail-Beigi, F. and C. E. Pope. 1974. Distribution of the histological changes of gastroesophageal reflux in the distal esophagus of man. Gastroenterology 66:1109-1113.
11. Simon, L. S. 1999. Role and regulation of Cyclooxigenase-2 during inflammation. Am. J. Med. 160(5B):37S-42S.
12. Lanas, A., Y. Royo, J. Ortego, M. Molina, and R. Sainz. 1999. Experimental esophagitis induced by acid and pepsin in rabbits mimicking human reflux esophagitis. Gastroenterology. 116(1):97-107.
13. Arceiz, E., A. Lanas, J. Ortego, and R. Sainz. 1997. Platelet-derived growth factor reverses the effects induced by NSAIDS on ulcer healing. Eur. J. Gastroenterol. Hepatol. 9(12):1179-1184.
14. Arroyo, M. T., A. Lanas, and R. Sainz. 2000. Prevention and healing of indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine. Eur. J. Gasterenterol. Hepatol. 12(3):313-318.
15. Kobayashi, S. and T. Kasuagi. 1974. Endoscopic and biopsy criteria for the diagnosis of esophagitis with a fiberoptic esophagoscope. Am. J. Dig. Dis. 19:345-352.
16. Lewin, K. J., R. H. Ridell, and W. M. Weinstein. 1992. Gastrointestinal pathology and its clinical implications. Volume I. New York: Igaku-Shoin, 404-411.
17. Powell, W. S. 1986. Reversed-phase high-pressure liquid chromatography of araquidonic acid metabolites formed by cyclooxygenase and lipooxygenase. Anal. Bioeh. 154:332-337.
18. Mizuno, H., C. Sakamoto, K. Matsuda, K. Wada, T. Uchida, H. Noguchi, T. Akamatsu, and M. Kasuga. 1997. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology, 112:387-397.
19. Soteras, F., A. Lanas, I. Fitene, Y. Royo, P. Jimenez, P. Iñarrea, J. Ortego, and F. Esteva. 2000. Nitric oxide and superoxide anion in low grade esophagitis induced by acid and pepsin in rabbits. Dig. Dis. Sci. 45:1802-1809.
20. Riendeau, D., M. D. Percival, S, Boyce, S. Brideau, S. Charleson, and W. Cromlish, et al. 1997. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121:105-117.
21. Jimenez, P., A. Lanas, E. Piazuelo, G. Bioque, and F. Esteva, 1997. Prostaglandin E2 is the major arachidonic acid metabolite secreted by esophageal mucosal cells in rabbits. Inflammation. 21(4):419-429.
22. Ottignon, Y., D. Alber, C. Moussard, J. P. Deschamps, P. Carayon, and J. C. Henry. 1987. Esophageal mucosal prostaglandin E2 levels in health and in gastroesophageal reflux disease. Prostaglandins Leukot. Med. 29(2-3):141-151.
23. Goddard, P. J., Y. J. Kao, and L. M. Lightenberger. 1990. Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel. Gastroenterology. 98:361-370.
24. Wallace, J. L., C. M. Keenan, and D. N. Granger. 1990. Gastric ulceration induced by nonsteriodal antiinflammatory drugs is a neutrophil-dependent process. Am. J. Physiol. 259:G462-G467.
25. Needleman, P. and P. C. Isakson. 1997. The discovery and function of COX-2. J. Rheumatol. 24 Suppl. 49:6-8.
26. Reuter, B. K., S. Asfaha, A. Buret, K. A. Sharkey, and J. L. Wallace. 1996. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest. 98:2076-2085.
27. Wilson, K. T., S. Fu, K. S. Ramanujan, and S. J. Meltzer. 1998. Increased expression of nitric oxide shyntase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Research. 58:2929-2934.
28. Shrivani, V. N., R. Ouatu-Lascar, B. S. Kaur, M. B. Omary, and G. Triadafilopoulos. 2000. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 118:487-496.
29. Morris, C. D., G. R. Armstrong, G. Bigley, H. Green, and S. E. Attwood. 2001. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 96(4):990-996.
30. Lanas, A., F. Soteras, P. Jimenez, I. Fiteni, E. Piazuelo, Y. Royo, J. Ortego, P. Iñarrea, and F. Esteva. 2001. Superoxide anion and nitric oxide in high grade esophagitis induced by acid and pepsin in rabbits. Dig. Dis. Sci. 46:2733-2743.
31. Patrignani, P., M. R. Panara, A. Greco, O. Fusco, C. Natoli, S. Iacobelli, and R. Cipollone, et al. 1994. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271(3):1705-1712.
32. Hayllar, J. and I. Bjarnason. 1995. NSAIDs, COX-2 inhibitors, and the gut. Lancet. 26; 346(8974):521-522.
33. Crofford. L. J., P. E. Lipsky, P. Brooks, S. B. Abramson, L. S. Simon, and L. B. A. Putte. 2000. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 43(1):4-13.